pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Lutathera · news · pharmadog
← back to Lutathera
News mentioning Lutathera
19
stories
6d
3 steps for taking on Novartis in radiopharma: Curium up first
biospace
11d
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
biospace
12d
Novartis secures new radioligand in $900M deal as competition strengthens
fiercebiotech
13d
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
biospace
13d
Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
biospace
13d
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
13d
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
biopharma dive
14d
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
fiercebiotech
19d
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
19d
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
19d
FDA approves first radioligand generic, setting up rivalry with Novartis
endpoints
Aug 12, 26
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
Aug 10, 26
FDA rejects ITM's radiopharma drug over manufacturing problems
endpoints
Aug 10, 26
ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
fiercebiotech
Jul 22, 26
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
biospace
Jul 21, 26
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
fiercebiotech
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jun 8, 26
Precision under pressure: Logistic solutions for nuclear medicine scalability
biopharma dive
Apr 23, 26
Novartis' radioligand therapy Lutathera could soon face generic competition
endpoints
